Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tuma

Showing results (11-20 of 102) with videos related to

Pageof 11
Sort By:
Journal of the National Cancer Institute|December 22, 2009
Origin of ovarian cancer may have implications for screeningRabiya S Tuma
Journal of the National Cancer Institute|November 1, 2007
Business barriers slowing the pace of cancer immunotherapy research and developmentRabiya S Tuma
Journal of the National Cancer Institute|October 11, 2007
Combining carefully selected drug, patient genetics may lead to total tumor deathRabiya S Tuma
Journal of the National Cancer Institute|February 20, 2003
Dosing study seen as victory for clinical trials, mathematical modelsRabiya S Tuma
Journal of the National Cancer Institute|July 4, 2002
Retinoids and lung cancer: targeting the right populationRabiya S Tuma
Journal of the National Cancer Institute|January 5, 2012
ALK gene amplified in most inflammatory breast cancersRabiya S Tuma
Journal of the National Cancer Institute|March 3, 2005
Trial and error: prognostic gene signature study design alteredRabiya S Tuma
Journal of the National Cancer Institute|July 21, 2005
New studies look beyond EGFR mutations for clues to sensitivity to erlotinibRabiya S Tuma
Journal of the National Cancer Institute|January 31, 2008
Examining heterogeneity in phase II trial designs may improve success in phase IIIRabiya S Tuma
Journal of the National Cancer Institute|March 28, 2008
Biomarker developers face big hurdlesRabiya S Tuma
Pageof 11

Showing results (11-20 of 102) with videos related to

Sort By:
Pageof 11
Journal of the National Cancer Institute|December 22, 2009
Origin of ovarian cancer may have implications for screeningRabiya S Tuma
Journal of the National Cancer Institute|November 1, 2007
Business barriers slowing the pace of cancer immunotherapy research and developmentRabiya S Tuma
Journal of the National Cancer Institute|October 11, 2007
Combining carefully selected drug, patient genetics may lead to total tumor deathRabiya S Tuma
Journal of the National Cancer Institute|February 20, 2003
Dosing study seen as victory for clinical trials, mathematical modelsRabiya S Tuma
Journal of the National Cancer Institute|July 4, 2002
Retinoids and lung cancer: targeting the right populationRabiya S Tuma
Journal of the National Cancer Institute|January 5, 2012
ALK gene amplified in most inflammatory breast cancersRabiya S Tuma
Journal of the National Cancer Institute|March 3, 2005
Trial and error: prognostic gene signature study design alteredRabiya S Tuma
Journal of the National Cancer Institute|July 21, 2005
New studies look beyond EGFR mutations for clues to sensitivity to erlotinibRabiya S Tuma
Journal of the National Cancer Institute|January 31, 2008
Examining heterogeneity in phase II trial designs may improve success in phase IIIRabiya S Tuma
Journal of the National Cancer Institute|March 28, 2008
Biomarker developers face big hurdlesRabiya S Tuma
Pageof 11